Serotonin and serotonin transporter in the rectum of patients with irritable bowel disease

El‑Salhy,Magdy; Wendelbo,Ingvild; Gundersen,Doris

doi:10.3892/mmr.2013.1525

Serotonin and serotonin transporter in the rectum of patients with irritable bowel disease

Authors:
- Magdy El‑Salhy
- Ingvild Wendelbo
- Doris Gundersen
View Affiliations

Affiliations: Section for Gastroenterology, Department of Medicine, Stord Helse‑Fonna Hospital, 5416 Stord, Norway, Section for Gastroenterology, Institute of Medicine, University of Bergen, 5029 Bergen, Norway, Department of Research, Helse‑Fonna, 5528 Haugesund, Norway
Published online on: June 14, 2013 https://doi.org/10.3892/mmr.2013.1525
Pages: 451-455

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder, which considerably reduces the quality of life of patients and represents an economic burden to society. In previous studies, the density of serotonin‑expressing cells in the rectum of IBS patients did not differ from that of control subjects. The present study was undertaken to investigate the immunoreactivity intensity of serotonin and serotonin‑selective reuptake transporter (SERT) in the rectum of IBS patients. A cohort of 50 patients with IBS (41 females and 9 males) were included in the study. Thirty patients had diarrhoea (IBS‑D) and 20 had constipation (IBS‑C) as the predominant symptom. Twenty‑seven subjects were included as controls (19 females and 8 males). Rectal biopsy specimens were immunostained using the avidin‑biotin complex method for serotonin and SERT. The immunoreactivity intensity was quantified by computerised image analysis using Olympus cell Sens imaging software. There was no statistical difference of serotonin immunoreactivity intensity in multiple comparisons between controls, IBS‑total, IBS‑D and IBS‑C. Dunn's post test did not reveal any statistical differences among the four groups. There was a significant statistical difference in multiple comparisons between controls, IBS‑total, IBS‑D and IBS‑C regarding the SERT immunoreactivity intensity. SERT immunoreactivity intensity of IBS‑total, IBS‑D and IBS‑C differed significantly from that of controls. It was concluded that the reduced rectal SERT in the IBS patients could be one of the factors contributing to the development of both diarrhoea and constipation in these patients, and that the increasing body of evidence of a genetic abnormality involving SERT underlines the importance of the role of SERT in the pathophysiology of IBS.

View Figures

View References

1	Thompson WG: A world view of IBS. Irritable Bowel Syndrome. Camilleri M and Spiller RC: Saunders; Philadelphia and London: pp. 17–26. 2002
2	Drossman DA, Li Z, Andruzzi E, et al: U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 38:1569–1580. 1993. View Article : Google Scholar : PubMed/NCBI
3	El-Salhy M, Gundersen D, Hatlebakk JG and Hausken T: Irritable Bowel Syndrome: Diagnosis, Pathogenesis and Treatment Options. Nova Science Publishers Inc; New York: 2012
4	Ford AC and Vandvik PO: Irritable bowel syndrome. Clin Evid (Online). 2012:pii04102012.
5	Lovell RM and Ford AC: Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 10:712–721.e4. 2012. View Article : Google Scholar : PubMed/NCBI
6	Quigley EM, Locke GR, Mueller-Lissner S, et al: Prevalence and management of abdominal cramping and pain: a multinational survey. Aliment Pharmacol Ther. 24:411–419. 2006. View Article : Google Scholar : PubMed/NCBI
7	Vandvik PO, Lydersen S and Farup PG: Prevalence, comorbidity and impact of irritable bowel syndrome in Norway. Scand J Gastroenterol. 41:650–656. 2006. View Article : Google Scholar : PubMed/NCBI
8	Saito YA, Schoenfeld P and Locke GR 3rd: The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 97:1910–1915. 2002.PubMed/NCBI
9	Whitehead WE, Burnett CK, Cook EW 3rd and Taub E: Impact of irritable bowel syndrome on quality of life. Dig Dis Sci. 41:2248–2253. 1996. View Article : Google Scholar : PubMed/NCBI
10	Agreus L, Svardsudd K, Nyren O and Tibblin G: Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology. 109:671–680. 1995. View Article : Google Scholar : PubMed/NCBI
11	Thompson WG and Heaton KW: Functional bowel disorders in apparently healthy people. Gastroenterology. 79:283–288. 1980.PubMed/NCBI
12	Kennedy TM, Jones RH, Hungin AP, O’Flanagan H and Kelly P: Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the general population. Gut. 43:770–774. 1998. View Article : Google Scholar : PubMed/NCBI
13	Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR and Evans RW: Medical costs in community subjects with irritable bowel syndrome. Gastroenterology. 109:1736–1741. 1995. View Article : Google Scholar : PubMed/NCBI
14	Hungin AP, Whorwell PJ, Tack J and Mearin F: The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 17:643–650. 2003. View Article : Google Scholar : PubMed/NCBI
15	Jones R and Lydeard S: Irritable bowel syndrome in the general population. BMJ. 304:87–90. 1992. View Article : Google Scholar : PubMed/NCBI
16	Bordie AK: Functional disorders of the colon. J Indian Med Assoc. 58:451–456. 1972.PubMed/NCBI
17	O’Keefe EA, Talley NJ, Zinsmeister AR and Jacobsen SJ: Bowel disorders impair functional status and quality of life in the elderly: a population-based study. J Gerontol A Biol Sci Med Sci. 50:M184–M189. 1995.PubMed/NCBI
18	Everhart JE and Renault PF: Irritable bowel syndrome in office-based practice in the United States. Gastroenterology. 100:998–1005. 1991.PubMed/NCBI
19	Wilson S, Roberts L, Roalfe A, Bridge P and Singh S: Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract. 54:495–502. 2004.PubMed/NCBI
20	Harvey RF, Salih SY and Read AE: Organic and functional disorders in 2000 gastroenterology outpatients. Lancet. 1:632–634. 1983. View Article : Google Scholar : PubMed/NCBI
21	Spiegel BM: The burden of IBS: looking at metrics. Curr Gastroenterol Rep. 11:265–269. 2009. View Article : Google Scholar : PubMed/NCBI
22	Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F and Spiller RC: Functional bowel disorders. Gastroenterology. 130:1480–1491. 2006. View Article : Google Scholar : PubMed/NCBI
23	Drossman DA: Rome III: the new criteria. Chin J Dig Dis. 7:181–185. 2006. View Article : Google Scholar : PubMed/NCBI
24	Harvey RF, Mauad EC and Brown AM: Prognosis in the irritable bowel syndrome: a 5-year prospective study. Lancet. 1:963–965. 1987.PubMed/NCBI
25	Norgaard M, Farkas DK, Pedersen L, et al: Irritable bowel syndrome and risk of colorectal cancer: a Danish nationwide cohort study. Br J Cancer. 104:1202–1206. 2011. View Article : Google Scholar : PubMed/NCBI
26	Sloth H and Jorgensen LS: Chronic non-organic upper abdominal pain: diagnostic safety and prognosis of gastrointestinal and non-intestinal symptoms. A 5- to 7-year follow-up study. Scand J Gastroenterol. 23:1275–1280. 1988.PubMed/NCBI
27	Pace F, Molteni P, Bollani S, et al: Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. Scand J Gastroenterol. 38:1031–1038. 2003. View Article : Google Scholar : PubMed/NCBI
28	Gralnek IM, Hays RD, Kilbourne A, Naliboff B and Mayer EA: The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 119:654–660. 2000. View Article : Google Scholar : PubMed/NCBI
29	Drossman DA, Morris CB, Schneck S, et al: International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 43:541–550. 2009. View Article : Google Scholar : PubMed/NCBI
30	Sandler RS, Everhart JE, Donowitz M, et al: The burden of selected digestive diseases in the United States. Gastroenterology. 122:1500–1511. 2002. View Article : Google Scholar : PubMed/NCBI
31	Coates MD, Johnson AC, Greenwood-Van Meerveld B and Mawe GM: Effects of serotonin transporter inhibition on gastrointestinal motility and colonic sensitivity in the mouse. Neurogastroenterol Motil. 18:464–471. 2006. View Article : Google Scholar : PubMed/NCBI
32	Wang SH, Dong L, Luo JY, et al: Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome. World J Gastroenterol. 13:6041–6047. 2007. View Article : Google Scholar : PubMed/NCBI
33	Kim HS, Lim JH, Park H and Lee SI: Increased immunoendocrine cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute Shigella infection - an observation in a small case control study. Yonsei Med J. 51:45–51. 2010.
34	Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK and Cho SW: The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol. 23:1689–1694. 2008. View Article : Google Scholar : PubMed/NCBI
35	Park JH, Rhee PL, Kim G, et al: Enteroendocrine cell counts correlate with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 18:539–546. 2006. View Article : Google Scholar : PubMed/NCBI
36	Dunlop SP, Jenkins D, Neal KR and Spiller RC: Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 125:1651–1659. 2003. View Article : Google Scholar : PubMed/NCBI
37	Spiller RC, Jenkins D, Thornley JP, et al: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 47:804–811. 2000. View Article : Google Scholar
38	El-Salhy M, Lomholt-Beck B and Hausken T: Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome. Scand J Gastroenterol. 45:1435–1439. 2010. View Article : Google Scholar : PubMed/NCBI
39	El-Salhy M, Mazzawi T, Gundersen D and Hausken T: Chromogranin A cell density in the rectum of patients with irritable bowel syndrome. Mol Med Rep. 6:1223–1225. 2012.PubMed/NCBI
40	El-Salhy M, Lillebo E, Reinemo A and Salmelid L: Ghrelin in patients with irritable bowel syndrome. Int J Mol Med. 23:703–707. 2009. View Article : Google Scholar : PubMed/NCBI
41	Dizdar V, Spiller R, Singh G, et al: Relative importance of abnormalities of CCK and 5-HT (serotonin) in Giardia-induced post-infectious irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 31:883–891. 2010.PubMed/NCBI
42	El-Salhy M, Vaali K, Dizdar V and Hausken T: Abnormal small-intestinal endocrine cells in patients with irritable bowel syndrome. Dig Dis Sci. 55:3508–3513. 2010. View Article : Google Scholar : PubMed/NCBI
43	El-Salhy M, Gundersen D, Ostgaard H, Lomholt-Beck B, Hatlebakk JG and Hausken T: Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. Dig Dis Sci. 57:873–878. 2012. View Article : Google Scholar : PubMed/NCBI
44	El-Salhy M and Mahdavi J: Image analysis of the duodenal endocrine cells in mice with special reference to optic densitomertry. Ups J Med Sci. 102:175–184. 1997. View Article : Google Scholar
45	Coates MD, Mahoney CR, Linden DR, et al: Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology. 126:1657–1664. 2004. View Article : Google Scholar
46	Mawe GM, Coates MD and Moses PL: Review article: intestinal serotonin signalling in irritable bowel syndrome. Aliment Pharmacol Ther. 23:1067–1076. 2006. View Article : Google Scholar : PubMed/NCBI
47	Erspamer V: Occurrence and distribution of 5-hydroxytryptamine (enteramine) in the living organism. Z Vitam Horm Fermentforsch. 9:74–96. 1957.PubMed/NCBI
48	Chen JX, Pan H, Rothman TP, Wade PR and Gershon MD: Guinea pig 5-HT transporter: cloning, expression, distribution, and function in intestinal sensory reception. Am J Physiol. 275:G433–G448. 1998.PubMed/NCBI
49	Spiller R and Lam C: An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. J Neurogastroenterol Motil. 18:258–268. 2012. View Article : Google Scholar : PubMed/NCBI
50	Keating C, Beyak M, Foley S, et al: Afferent hypersensitivity in a mouse model of post-inflammatory gut dysfunction: role of altered serotonin metabolism. J Physiol. 586:4517–4530. 2008. View Article : Google Scholar : PubMed/NCBI
51	Coleman NS, Foley S, Dunlop SP, et al: Abnormalities of serotonin metabolism and their relation to symptoms in untreated celiac disease. Clin Gastroenterol Hepatol. 4:874–881. 2006. View Article : Google Scholar : PubMed/NCBI
52	Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD and Gershon MD: Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J Neurosc. 16:2352–2364. 1996.PubMed/NCBI
53	Chen JJ, Li Z, Pan H, et al: Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J Neurosci. 21:6348–6361. 2001.PubMed/NCBI
54	Faure C, Patey N, Gauthier C, Brooks EM and Mawe GM: Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. Gastroenterology. 139:249–258. 2010. View Article : Google Scholar : PubMed/NCBI
55	Kim HJ, Camilleri M, Carlson PJ, et al: Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut. 53:829–837. 2004. View Article : Google Scholar
56	Camilleri M, Andrews CN, Bharucha AE, et al: Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology. 132:17–25. 2007. View Article : Google Scholar : PubMed/NCBI
57	Camilleri M, Busciglio I, Carlson P, et al: Candidate genes and sensory functions in health and irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 295:G219–G225. 2008. View Article : Google Scholar : PubMed/NCBI
58	Kumar S, Ranjan P, Mittal B and Ghoshal UC: Serotonin transporter gene (SLC6A4) polymorphism in patients with irritable bowel syndrome and healthy controls. J Gastrointestin Liver Dis. 21:31–38. 2012.PubMed/NCBI
59	Park JM, Choi MG, Park JA, et al: Serotonin transporter gene polymorphism and irritable bowel syndrome. Neurogastroenterol Motil. 18:995–1000. 2006. View Article : Google Scholar : PubMed/NCBI
60	Saito YA, Locke GR 3rd, Zimmerman JM, et al: A genetic association study of 5-HTT LPR and GNbeta3 C825T polymorphisms with irritable bowel syndrome. Neurogastroenterol Motil. 19:465–470. 2007. View Article : Google Scholar : PubMed/NCBI
61	Colucci R, Blandizzi C, Bellini M, Ghisu N, Tonini M and Del Tacca M: The genetics of the serotonin transporter and irritable bowel syndrome. Trends in molecular medicine. 14:295–304. 2008. View Article : Google Scholar : PubMed/NCBI
62	Colucci R, Gambaccini D, Ghisu N, et al: Influence of the serotonin transporter 5HTTLPR polymorphism on symptom severity in irritable bowel syndrome. PloS One. 8:e548312013. View Article : Google Scholar : PubMed/NCBI
63	Park MI and Camilleri M: Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? A systematic review. Neurogastroenterol Motil. 18:595–607. 2006. View Article : Google Scholar : PubMed/NCBI